Cullinan Therapeutics has announced a licensing agreement with Genrix Bio for global rights to velinotamig, a clinical-stage ...

This program supports undergraduate, graduate, and medical students conducting lupus-focused research under the guidance of experienced mentors.

This special weekend retreat is designed for young girls ages 12-19 living with lupus. While parents are unable to attend, licensed medical volunteers, mentors, and LFA staff will be on-site at all ...

Jill, a lupus warrior dedicated to making a difference, has participated in the Virtual 6 Challenge every year since it began six years ago. Through her journey with lupus, she has found strength, ...

This June, we recognize Men’s Health Month by honoring the strength, challenges and lived experiences of men with lupus.

The Lupus Foundation of America (LFA) is excited to announce Karen Costenbader, MD, MPH, Lupus Program Director, Brigham and Women’s Hospital, Professor of Medicine at Harvard Medical School, and ...

In this episode of the Lupus Foundation of America's The Expert Series podcast, we explore the intersection of menopause and lupus, highlighting the unique challenges faced by women with lupus during ...

Having been diagnosed with lupus over 20 years ago, Kristine Falk occasionally had to call in sick to work due to her lupus symptoms. But on a fall day in 2011, she was off work for a different reason ...

Wondering if you have lupus or receiving a diagnosis of lupus can be challenging and stressful. We have put together some resources to help you find the support and information that you need. Our ...

Lupus affects different people in different ways. Many people with lupus have problems with their liver. How does lupus affect the liver? Your liver helps your body digest food and filters waste out ...

Today, the U.S. Food and Drug Administration (FDA) has accepted Genentech’s Supplemental Biologics License Application (sBLA) for Gazyva® (Obinutuzumab), for the potential treatment of lupus nephritis ...

The U.S. Food and Drug Administration (FDA) has placed a clinical hold on Kezar Life Sciences’ zetomipzomib, an investigational therapy for lupus nephritis (LN). This comes after Kezar Life Sciences ...